SRT2183 (SRT 2183; SRT-2183) is a novel and potent small-molecule activator of the sirtuin subtype1-(SIRT1, EC50 =0.36 μM) developed by Sirtris Pharmaceuticals as therapeutics for the treatment of type 2 diabetes and potentially leukemia as well. SRT2183 resembles resveratrol in potency but functions similarly in the body to another SIRT1 activator, SRT1720. It has been observed in animal studies to enhance insulin sensitivity, decrease liver, muscle, and fat tissue's plasma glucose levels, and boost mitochondrial and metabolic activity. The assertion that SRT2183 activates SIRT1 has been contested and then reaffirmed, though.
Physicochemical Properties
| Molecular Formula | C27H24N4O2S | |
| Molecular Weight | 468.57 | |
| Exact Mass | 468.162 | |
| Elemental Analysis | C, 69.21; H, 5.16; N, 11.96; O, 6.83; S, 6.84 | |
| CAS # | 1001908-89-9 | |
| Related CAS # |
|
|
| PubChem CID | 24180126 | |
| Appearance | White solid powder | |
| LogP | 5.045 | |
| Hydrogen Bond Donor Count | 2 | |
| Hydrogen Bond Acceptor Count | 5 | |
| Rotatable Bond Count | 5 | |
| Heavy Atom Count | 34 | |
| Complexity | 725 | |
| Defined Atom Stereocenter Count | 1 | |
| SMILES | S1C2=NC(C3=CC=CC=C3NC(C3C=CC4C=CC=CC=4C=3)=O)=CN2C(=C1)CN1CC[C@H](C1)O |
|
| InChi Key | MUFSINOSQBMSLE-JOCHJYFZSA-N | |
| InChi Code | InChI=1S/C27H24N4O2S/c32-22-11-12-30(15-22)14-21-17-34-27-29-25(16-31(21)27)23-7-3-4-8-24(23)28-26(33)20-10-9-18-5-1-2-6-19(18)13-20/h1-10,13,16-17,22,32H,11-12,14-15H2,(H,28,33)/t22-/m1/s1 | |
| Chemical Name | N-[2-[3-[[(3R)-3-hydroxypyrrolidin-1-yl]methyl]imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]naphthalene-2-carboxamide | |
| Synonyms |
|
|
| HS Tariff Code | 2934.99.9001 | |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | SIRT1 ( EC1.5 = 0.36 μM ) | ||
| ln Vitro |
|
||
| ln Vivo |
|
||
| Cell Assay | BMMs are harvested, plated, and 24-hour later, non-adherent cells were replated in α-MEM/15% FBS/5% M-CSF at a density of 20,000 cells/well. In order to assess cell proliferation, 72 hours after plating, cells are treated with SRT2183 or a vehicle. Then, 48 hours after SRT2183 or vehicle administration, BrdU reagent is added in accordance with manufacturer's instructions to assess cell proliferation three days after plating. | ||
| Animal Protocol |
|
||
| References |
[1]. Nature . 2007 Nov 29;450(7170):712-6. [2]. Blood (2009) 114 (22): 3083. [3]. J Biol Chem . 2010 Mar 12;285(11):8340-51. [4]. J Biol Chem . 2010 Mar 12;285(11):8340-51. |
Solubility Data
| Solubility (In Vitro) |
|
|||
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1342 mL | 10.6708 mL | 21.3415 mL | |
| 5 mM | 0.4268 mL | 2.1342 mL | 4.2683 mL | |
| 10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL |